[1] |
杨小孟.
中药丹参化学成分和临床应用的研究进展[J]. 中国民族民间医药, 2013, 22(9): 54–55.
|
|
[2] |
罗彩莲.
丹参的药理作用与临床应用[J]. 中国当代医药, 2012, 5(12): 11–12.
DOI:10.3969/j.issn.1674-4721.2012.12.006 |
|
[3] |
袁成刚, 范力, 杨兵.
丹参的临床应用进展[J]. 辽宁医学院学报, 2009, 30(4): 366–368.
|
|
[4] |
李卫祥.
丹参的药理作用与临床应用[J]. 北方药学, 2013, 24(3): 34–35.
|
|
[5] |
刘顺中.
近5年来丹参生药的鉴定和临床应用分析[J]. 中国医药指南, 2012, 10(21): 238–240.
DOI:10.3969/j.issn.1671-8194.2012.21.174 |
|
[6] |
周良楣.
中药丹参在临床上的应用[J]. 新中医, 1976, 5(3): 51–54.
|
|
[7] |
樊官伟, 何俊, 王虹, 等.
雌激素及其受体信号转导途径的研究进展[J]. 中国临床药理学与治疗学, 2007, 18(3): 266–269.
|
|
[8] |
郑向红, 许颖.
雌激素受体及与雌激素相关疾病的研究进展[J]. 海峡药学, 2016, 10(1): 1–5.
|
|
[9] |
Burger H.
Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003[J]. Climacteric, 2003, 6(Suppl 1): 11–36.
|
|
[10] |
于楠, 张喆, 郭佑民.
雌激素及其受体对肿瘤进展的影响[J]. 现代肿瘤医学, 2012, 20(11): 2438–2442.
DOI:10.3969/j.issn.1672-4992.2012.11.79 |
|
[11] |
朱迪娜, 王磊, 王思彤, 等.
植物雌激素的研究进展[J]. 中草药, 2012, 42(7): 1422–1429.
|
|
[12] |
陆亦宇, 苏式兵.
中药植物雌激素与乳腺癌的研究[J]. 中成药, 2010, 32(6): 1010–1014.
|
|
[13] |
Zhang JM, Li J, Liu EW, et al.
Danshen enhanced the estrogenic effects of Qing E formula in ovariectomized rats[J]. Bmc complementary and alternative medicine, 2016, 16(1): 1–10.
|
|
[14] |
Hsieh TC, Wu JM.
Differential control of growth, cell cycle progression, and geneexpression in human estrogen receptor positive MCF-7 breastcancer cells by extracts derived from polysaccharopeptideI'm-Yunity and Danshen and their combination[J]. International Journal of Oncology, 2006, 29(5): 1215–1222.
|
|
[15] |
牛建昭, 赵丕文, 王继锋, 等.
补骨脂等5种中药植物雌激素活性的实验研究[J]. 北京中医药大学学报, 2008, 31(10): 676–681.
DOI:10.3321/j.issn:1006-2157.2008.10.007 |
|
[16] |
赵丕文, 王大伟, 牛建昭, 等.
红花等10种中药的植物雌激素活性研究[J]. 中国中药杂志, 2007, 32(5): 436–439.
|
|
[17] |
周瑞芳. PE相关中药黄芪、丹参对人乳腺癌MCF-7、MDA-MB-231细胞增殖凋亡的影响[D]. 广州: 广州中医药大学, 2007.
http://cdmd.cnki.com.cn/Article/CDMD-10572-2008100015.htm |
|
[18] |
赵丕文, 王大伟, 王玲巧, 等.
用小鼠子宫增重法筛选淫羊藿等10种中药雌激素样作用的实验研究[J]. 北京中医药大学学报, 2006, 29(10): 686–689.
DOI:10.3321/j.issn:1006-2157.2006.10.011 |
|
[19] |
赵丕文. 10种中药植物雌激素样作用及其机制的研究[D]. 北京: 北京中医药大学, 2007.
http://cdmd.cnki.com.cn/Article/CDMD-10026-2007077882.htm |
|
[20] |
李春梅, 杨日福, 顾取良, 等.
丹参水提取物对去卵巢大鼠血脂和肝脏的影响[J]. 华南理工大学学报, 2012, 40(12): 151–156.
DOI:10.3969/j.issn.1000-565X.2012.12.026 |
|
[21] |
Xu Y, Chen T.
Salvia miltiorrhiza bunge increases estrogen level without side effects on reproductive tissues in immature/ovariectomized mice[J]. Aging (Albany NY), 2017, 9(1): 156–172.
|
|
[22] |
郭文宇, 刘灿灿, 董艺丹, 等.
中药对去势小鼠生殖系统及行为学的影响[J]. 江西中医药大学学报, 2015, 27(1): 82–85.
|
|
[23] |
陈莎莎. 乳块消方对乳腺增生模型大鼠作用及其机理的研究[D]. 广州: 广州中医药大学, 2007.
http://cdmd.cnki.com.cn/article/cdmd-10307-2008031280.htm |
|
[24] |
Weng YS, Kuo WW, Lin YM.
Danshen mediates through estrogen receptors to activate Akt and inhibit apoptosis effect of Leu27IGF-Ⅱ-induced IGF-Ⅱ receptor signaling activation in cardiomyoblasts[J]. Food and Chemical Toxicology, 2013, 56(1): 28–39.
|
|
[25] |
李春梅. 丹参、川芎提取物对高脂喂养去卵巢大鼠血脂和骨的作用及机制研究[D]. 广州: 华南理工大学, 2013.
http://cdmd.cnki.com.cn/Article/CDMD-10561-1013320420.htm |
|
[26] |
高玉桂, 王灵芝, 唐冀雪.
丹参酮的性激素样活性[J]. 中国医学科学院学报, 1980, 2(3): 189–191.
|
|
[27] |
韩鑫冰, 马淑兰, 王次霞, 等.
丹参酮加强电针对去卵巢大鼠下丘脑-垂体-卵巢轴异常功能的调整作用[J]. 上海针灸杂志, 2004, 23(10): 36–38.
DOI:10.3969/j.issn.1005-0957.2004.10.021 |
|
[28] |
李新梅, 董春梅, 苑丽华, 等.
丹参酮治疗原发性痛经203例临床分析[J]. 中国医师杂志, 2001, 3(6): 476.
|
|
[29] |
李隆敏, 周樱, 邵幸署, 等.
丹参酮防治绝经后骨质疏松症[J]. 中国骨质疏松杂志, 1996, 21(2): 78–80.
|
|
[30] |
周延萌, 刘玉波, 高允生.
丹参酮对维甲酸致小鼠骨质疏松的防治作用[J]. 中国中药杂志, 2010, 35(21): 2923–2926.
|
|
[31] |
孙艳玲. 丹参酮Ⅰ植物雌激素样作用及其机制的研究[D]. 广州: 广州中医药大学, 2012.
http://cdmd.cnki.com.cn/Article/CDMD-10026-1012362977.htm |
|
[32] |
赵丕文, 牛建昭, 王继锋.
6种中药活性成分植物雌激素作用的比较研究[J]. 中国药学杂志, 2007, 42(24): 1852–1855.
DOI:10.3321/j.issn:1001-2494.2007.24.004 |
|
[33] |
Nizamutdinova IT, Lee GW, Son KH.
Tanshinone Ⅰ effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells[J]. International Journal of Oncology, 2008, 33: 485–491.
|
|
[34] |
Nizamutdinova IT, Lee GW, Lee JS.
Tanshinone Ⅰ suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules[J]. Carcinogenesis, 2008, 29(10): 1885–1892.
DOI:10.1093/carcin/bgn151 |
|
[35] |
王丽. 丹参酮Ⅰ对人乳腺癌细胞的抑制作用及对PI3K/Akt/Mtor信号通路的影响[D]. 南京: 南京中医药大学, 2014.
http://cdmd.cnki.com.cn/Article/CDMD-10315-1015628766.htm |
|
[36] |
张蒲容. 丹参酮ⅡA对乳腺癌内分泌治疗的实验研究[D]. 南京: 南京中医药大学, 2007.
http://cdmd.cnki.com.cn/Article/CDMD-10610-2007220207.htm |
|
[37] |
Gong Y, Li Y, Abdolmaleky HM, et al.
Tanshinones Inhibit the Growth of Breast Cancer Cells through Epigenetic Modification of Aurora A Expression and Function[J]. Plos One, 2012, 7(4): e33656.
DOI:10.1371/journal.pone.0033656 |
|
[38] |
张蒲容, 吕青.
丹参酮ⅡA抗乳腺癌作用机制的实验研究[J]. 四川大学学报, 2009, 40(2): 245–249.
|
|
[39] |
惠文涛, 马小斌, 暂瑛, 等.
丹参酮ⅡA磺酸钠对乳腺癌细胞株的作用及其机制研究[J]. 陕西医学杂志, 2015, 44(7): 781–784.
|
|
[40] |
敬静, 郑鸿, 王静, 等.
丹参酮ⅡA对人ER阴性乳腺癌细胞的生长抑制和多耐药逆转作用[J]. 四川大学学报, 2007, 38(3): 391–395.
|
|
[41] |
杜睿, 郑鸿, 王艳萍, 等.
丹参酮ⅡA逆转人ER阳性乳腺癌细胞的恶性表型及其机理[J]. 华西药学杂志, 2009, 24(1): 35–38.
|
|
[42] |
赵丕文, 牛建昭, 王继锋, 等.
丹参酮ⅡA抗乳腺癌细胞增值作用研究[J]. 中国药理学通报, 2010, 26(7): 903–906.
|
|
[43] |
臧金凤. ER介导丹参酮ⅡA抗妇科肿瘤作用机制的研究[D]. 北京: 北京中医药大学, 2016.
http://cdmd.cnki.com.cn/Article/CDMD-10026-1016068807.htm |
|
[44] |
赵丕文, 臧金凤, 陶仕英, 等.
丹参酮ⅡA抗乳腺癌T47D细胞增殖的GPER途径研究[J]. 中国药理学通报, 2015, 31(10): 1458–1462.
DOI:10.3969/j.issn.1001-1978.2015.10.026 |
|
[45] |
臧金凤, 赵丕文, 赵俊云, 等.
丹参酮ⅡA抗宫颈癌鳞癌细胞增殖效应及其雌激素受体亚型介导机制的研究[J]. 中国中医药信息杂志, 2016, 23(6): 51–55.
|
|
[46] |
赵丕文, 臧金凤, 陶仕英, 等.
基因沉默技术研究丹参酮ⅡA抗雌激素受体阴性乳腺癌细胞增殖的GPER途径[J]. 中华中医药杂志, 2016, 31(11): 4502–4506.
|
|
[47] |
张欣, 张蒲容, 陈洁, 等.
丹参酮ⅡA对乳腺癌抑制作用的体内实验研究[J]. 四川大学学报, 2010, 41(1): 62–67.
|
|
[48] |
Lu Q, Zhang PR, Zhang X.
Experimental study of the anti-cancer mechanism of tanshinone ⅡA against human breast cancer[J]. International Journal of Molecular Medicine, 2009, 24: 773–780.
|
|
[49] |
梁江红, 罗蕊丽, 冷小飞.
丹参酮ⅡA对子宫内膜异位症大鼠的治疗作用[J]. 中国中医急症, 2016, 25(4): 612–615.
|
|
[50] |
Yao X, Wang XQ, Ma SL.
Sodium tanshinone ⅡA sulfonate derived from Slaviamiltiorrhiza Bunge up-regulate the expression of prolactin releasing peptide (PrRP) in the medulla oblongata in ovariectomized rats[J]. Biochemical Pharmacology, 2006, 72: 582–587.
DOI:10.1016/j.bcp.2006.05.014 |
|
[51] |
刘欣. 丹参酮ⅡA对血管内皮损伤的类雌激素样保护效应及机制研究[D]. 北京: 北京中医药大学, 2013.
http://cdmd.cnki.com.cn/Article/CDMD-10026-1013205476.htm |
|
[52] |
李健, 武彪, 李映良.
丹参酮ⅡA对人乳腺癌细胞MDA-MB-231作用的实验研究[J]. 军医进修学院学报, 2012, 33(7): 754–756.
|
|
[53] |
李健. 丹参酮ⅡA对人乳腺癌细胞MDA-MB-231作用的实验研究[D]. 南昌: 南昌大学, 2012.
http://kns.cnki.net/KCMS/detail/detail.aspx?filename=jyjx201207027&dbname=CJFD&dbcode=CJFQ |
|
[54] |
Shi C, Zhu X, Wang J, et al.
Tanshinone ⅡA promotes non-amyloidogenic processing of amyloid precursor protein in platelets via estrogen receptor signaling to phosphatidylinositol 3-kinase/Akt[J]. Biomed Rep, 2014, 2(4): 500–504.
DOI:10.3892/br.2014.263 |
|
[55] |
Fan GW, Zhu Y, Gao H.
Direct Vasorelaxation by a Novel Phytoestrogen Tanshinone ⅡA Is Mediated by Nongenomic Action ofEstrogen Receptor Through Endothelial Nitric Oxide Synthase Activation and Calcium Mobilization[J]. J CardiovascPharmacol, 2011, 57(3): 340–347.
|
|
[56] |
Fan GW, Gao XM, Wang H.
The anti-inflammator y activities of Tanshinone ⅡA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS[J]. Journal of Steroid Biochemistry and Molecular Biology, 2009, 113(1): 275–280.
|
|
[57] |
Weng YS, Wang HF, Pai PY, et al.
Tanshinone ⅡA preventsLeu27IGF-Ⅱ-Induced cardiomyocytehypertrophy mediated by estrogenreceptor and subsequent aktactivation[J]. The American Journal of Chinese Medicine, 2015, 43(8): 1567–1591.
DOI:10.1142/S0192415X15500895 |
|
[58] |
Zhao P, Soukup ST, Hegevoss J, et al.
Anabolic effect of the traditional chinese medicine compound tanshinone ⅡA on myotube hypertrophy is mediated by estrogen receptor[J]. Planta Med, 2015, 81: 578–585.
DOI:10.1055/s-00000058 |
|
[59] |
Wang X, Bastow KF, Sun C, et al.
Antitumor Agents. Part 239. Isolation, Structure Elucidation, Total Synthesis, and anti-Breast Cancer Activity of Neo-tanshinlactone from Salvia miltiorrhiza[J]. Journal of Medicinal Chemistry, 2004, 47(23): 5816–5819.
DOI:10.1021/jm040112r |
|
[60] |
Lin WJ, Huang JJ, Liao XL, et al.
Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha[J]. Pharmacological Research, 2016, 111(3): 849–858.
|
|
[61] |
Fernandez E, Gallus S, Bosetti C, et al.
Hormone replacement therapy and cancer risk:a systematic analysis from a network of case-control studies[J]. International Journal of Cancer, 2003, 105(3): 408–412.
DOI:10.1002/(ISSN)1097-0215 |
|
[62] |
Humphries KH, Gill S, Mansour J.
Risks and benefits of hormone replacement therapy:the evidence speaks[J]. CMAJ, 2003, 168(8): 1001–1010.
|
|
[63] |
宋丽华.
植物性雌激素研究进展[J]. 国外医学:药学分册, 2003, 30(1): 25–29.
|
|
[64] |
Sirtori CR.
Risks and benefits of soy phytoestrogens in cardiovascular disease, cancer, climacteric symptoms and osteoporosis[J]. Drug Saf, 2001, 24(9): 665–682.
DOI:10.2165/00002018-200124090-00003 |
|
[65] |
Teede HJ, Delais FS, Kotsopoulos D, et al.
Dietary soy has both beneficial and potentially adverse cardiovascular effect:a placebo-controlled study in men and postmenopausal women[J]. J Clin Endocrinol Metab, 2001, 86(7): 3053–3060.
|
|